N-(4-Isopropylamino-phenyl)-piperidin | 13663-26-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(4-Isopropylamino-phenyl)-piperidin
• 英文别名: 4-piperidin-1-yl-N-propan-2-ylaniline
• CAS: 13663-26-8
• 化学式: C₁₄H₂₂N₂
• mdl: MFCD12146979
• 分子量: 218.342
• InChiKey: JFRFJXPGDMLFRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY<br/>[FR] DÉRIVÉS TRIAZOLES À ACTIVITÉ ANTIFONGIQUE
  申请人：KING S COLLEGE LONDON

  公开号：WO2021156636A1

  公开（公告）日：2021-08-12

  Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, Q2, L1 and n are as defined herein. The compounds have antifungal properties and are useful in the treatment of fungal infections, including infections that are resistant to conventions anti-fungal agents. Q1 is selected from: (Formulae Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij and Ik) wherein * indicates the point of attachment to L1.

  揭示了公式(I)的化合物及其药学上可接受的盐，其中R1、R2、Q2、L1和n的定义如本文所述。这些化合物具有抗真菌性能，并可用于治疗真菌感染，包括对传统抗真菌药物产生耐药性的感染。Q1选自:(公式Ia、Ib、Ic、Id、Ie、If、Ig、Ih、Ii、Ij和Ik)，其中*表示与L1的连接点。
• SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS
  申请人：Bearss David J.

  公开号：US20130059847A1

  公开（公告）日：2013-03-07

  In one aspect, the invention relates to substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the BTK kinase; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the BTK kinase. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在某个方面，本发明涉及取代的N-(3-(嘧啶-4-基)苯基)丙烯酰胺类似物、其衍生物和相关化合物，这些化合物可用作BTK激酶的抑制剂；制备这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与BTK激酶功能障碍相关的疾病的方法。本摘要旨在作为特定领域搜索的扫描工具，不限制本发明。
• NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20160130304A1

  公开（公告）日：2016-05-12

  The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
• METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US20160311807A1

  公开（公告）日：2016-10-27

  The present invention provides compounds of any one of Formulae (I) to (V) (e.g., compounds of any one of Formulae (I-1) to (I-9)), and methods for treating Waldenström's macroglobulinemia (WM) and other B cell neoplams in a subject using the compounds. The methods comprise administering to a subject in need thereof an effective amount of the compounds. Also provided are methods to treat B cell neoplasms using the compounds in combination with inhibitors of Bruton's tyrosine kinase (BTK), interleukin-1 receptor-associated kinase 1 (IRAK1), interleukin-1 receptor-associated kinase 4 (IRAK4), bone marrow on X chromosome kinase (BMX), phosphoinositide 3-kinase (PI3K), transforming growth factor b-activated kinase-1 (TAK1), and/or a Src family kinase.
• US9206176B2
  申请人：——

  公开号：US9206176B2

  公开（公告）日：2015-12-08